Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms

References

• Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet365(9467), 1333–1346 (2005).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2009. Diabetes Care32(Suppl. 1), S13–S61 (2009).
   PubMed Web of Science ®Google Scholar
• No authors listed. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) group. Lancet352(9131), 837–853 (1998).
   PubMed Web of Science ®Google Scholar
• No authors listed. Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) group. Lancet352(9131), 854–865 (1998).
   PubMed Web of Science ®Google Scholar
• Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res. Clin. Pract.28(2), 103–117 (1995).
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in Type 2 diabetes. N. Engl. J. Med.359(15), 1577–1589 (2008).
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in Type 2 diabetes. N. Engl. J. Med.358(24), 2545–2559 (2008).
   PubMed Web of Science ®Google Scholar
• Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with Type 2 diabetes. N. Engl. J. Med.358(24), 2560–2572 (2008).
   PubMed Web of Science ®Google Scholar
• Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with Type 2 diabetes. N. Engl. J. Med.360(2), 129–139 (2009).
   PubMed Web of Science ®Google Scholar
• Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J. Systematic review: glucose control and cardiovascular disease in Type 2 diabetes. Ann. Intern. Med.151(6), 394–403 (2009).
   PubMed Web of Science ®Google Scholar
• Ray KK, Seshasai SR, Wijesuriya S et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet373(9677), 1765–1772 (2009).
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care32(1), 193–203 (2009).
   PubMed Web of Science ®Google Scholar
• Roden DM, Altman RB, Benowitz NL et al. Pharmacogenomics: challenges and opportunities. Ann. Intern. Med.145(10), 749–757 (2006).
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockmoller J. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin. Pharmacokinet.44(12), 1209–1225 (2005).
   PubMed Web of Science ®Google Scholar
• Pacanowski MA, Hopley CW, Aquilante CL. Interindividual variability in oral antidiabetic drug disposition and response: the role of drug transporter polymorphisms. Expert Opin. Drug Metab. Toxicol.4(5), 529–544 (2008).
   PubMed Web of Science ®Google Scholar
• Murphy R, Ellard S, Hattersley AT. Clinical implications of a molecular genetic classification of monogenic β-cell diabetes. Nat. Clin. Pract. Endocrinol. Metab.4(4), 200–213 (2008).
   PubMedGoogle Scholar
• Gloyn AL, Ellard S. Defining the genetic aetiology of monogenic diabetes can improve treatment. Expert Opin. Pharmacother.7(13), 1759–1767 (2006).
   PubMed Web of Science ®Google Scholar
• Reis AF, Velho G. Sulfonylurea receptor-1 (SUR1): genetic and metabolic evidences for a role in the susceptibility to Type 2 diabetes mellitus. Diabetes Metab.28(1), 14–19 (2002).
   Google Scholar
• Marchetti P, Navalesi R. Pharmacokinetic–pharmacodynamic relationships of oral hypoglycaemic agents. An update. Clin. Pharmacokinet.16(2), 100–128 (1989).
   PubMed Web of Science ®Google Scholar
• Efanova IB, Zaitsev SV, Zhivotovsky B et al. Glucose and tolbutamide induce apoptosis in pancreatic β-cells. A process dependent on intracellular Ca2+ concentration. J. Biol. Chem.273(50), 33501–33507 (1998).
   PubMed Web of Science ®Google Scholar
• Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced β-cell apoptosis in cultured human islets. J. Clin. Endocrinol. Metab.90(1), 501–506 (2005).
   PubMed Web of Science ®Google Scholar
• Del Guerra S, Marselli L, Lupi R et al. Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets. J. Diabetes Complicat.19(1), 60–64 (2005).
   PubMed Web of Science ®Google Scholar
• Del Prato S, Pulizzi N. The place of sulfonylureas in the therapy for Type 2 diabetes mellitus. Metabolism55(5 Suppl. 1), S20–S27 (2006).
   PubMed Web of Science ®Google Scholar
• Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in Type 2 diabetes mellitus. Drugs65(3), 385–411 (2005).
   PubMed Web of Science ®Google Scholar
• Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes19(Suppl.), 789–830 (1970).
   PubMed Web of Science ®Google Scholar
• Thisted H, Johnsen SP, Rungby J. Sulfonylureas and the risk of myocardial infarction. Metabolism55(5 Suppl. 1), S16–S19 (2006).
   PubMed Web of Science ®Google Scholar
• Kar P, Holt RI. The effect of sulphonylureas on the microvascular and macrovascular complications of diabetes. Cardiovasc. Drugs Ther.22(3), 207–213 (2008).
   PubMed Web of Science ®Google Scholar
• Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR, Holman RR. Risk factors for myocardial infarction case fatality and stroke case fatality in Type 2 diabetes: UKPDS 66. Diabetes Care27(1), 201–207 (2004).
   PubMed Web of Science ®Google Scholar
• DeFronzo RA. Pharmacologic therapy for Type 2 diabetes mellitus. Ann. Intern. Med.131(4), 281–303 (1999).
   PubMed Web of Science ®Google Scholar
• Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med.355(23), 2427–2443 (2006).
   PubMed Web of Science ®Google Scholar
• Kirchheiner J, Bauer S, Meineke I et al. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics12(2), 101–109 (2002).
   PubMedGoogle Scholar
• Kirchheiner J, Brockmoller J, Meineke I, et al. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin. Pharmacol. Ther.71(4), 286–296 (2002).
   PubMed Web of Science ®Google Scholar
• Becker ML, Visser LE, Trienekens PH, Hofman A, van Schaik RH, Stricker BH. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in Type II diabetes mellitus. Clin. Pharmacol. Ther.83(2), 288–292 (2008).
   PubMed Web of Science ®Google Scholar
• Zhou K, Donnelly L, Burch L et al. Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in Type 2 diabetes: a Go-DARTS study. Clin. Pharmacol. Ther.87(1), 52–56 (2009).
   Google Scholar
• Holstein A, Plaschke A, Ptak M et al. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br. J. Clin. Pharmacol.60(1), 103–106 (2005).
   PubMed Web of Science ®Google Scholar
• Flanagan SE, Clauin S, Bellanne-Chantelot C et al. Update of mutations in the genes encoding the pancreatic β-cell KATP channel subunits Kir6.2 (KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism. Hum. Mutat.30(2), 170–180 (2009).
   PubMed Web of Science ®Google Scholar
• Sattiraju S, Reyes S, Kane GC, Terzic A. KATP channel pharmacogenomics: from bench to bedside. Clin. Pharmacol. Ther.83(2), 354–357 (2008).
   PubMedGoogle Scholar
• Rafiq M, Flanagan SE, Patch AM, Shields BM, Ellard S, Hattersley AT. Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care31(2), 204–209 (2008).
   PubMed Web of Science ®Google Scholar
• Pearson ER, Flechtner I, Njolstad PR et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N. Engl. J. Med.355(5), 467–477 (2006).
   PubMed Web of Science ®Google Scholar
• Hansen T, Echwald SM, Hansen L et al. Decreased tolbutamide-stimulated insulin secretion in healthy subjects with sequence variants in the high-affinity sulfonylurea receptor gene. Diabetes47(4), 598–605 (1998).
   PubMed Web of Science ®Google Scholar
• Meirhaeghe A, Helbecque N, Cottel D et al. Impact of sulfonylurea receptor 1 genetic variability on non-insulin-dependent diabetes mellitus prevalence and treatment: a population study. Am. J. Med. Genet.101(1), 4–8 (2001).
   PubMed Web of Science ®Google Scholar
• Zychma MJ, Gumprecht J, Strojek K et al. Sulfonylurea receptor gene 16–13 polymorphism – association with sulfonylurea or insulin treatment in Type 2 diabetic subjects. Med. Sci. Monit.8(7), CR512–CR515 (2002).
   Google Scholar
• Florez JC, Jablonski KA, Kahn SE et al. Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program. Diabetes56(2), 531–536 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang H, Liu X, Kuang H, Yi R, Xing H. Association of sulfonylurea receptor 1 genotype with therapeutic response to gliclazide in Type 2 diabetes. Diabetes Res. Clin. Pract.77(1), 58–61 (2007).
   PubMed Web of Science ®Google Scholar
• Feng Y, Mao G, Ren X et al. Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese Type 2 diabetic patients. Diabetes Care31(10), 1939–1944 (2008).
   PubMed Web of Science ®Google Scholar
• Gloyn AL, Hashim Y, Ashcroft SJ, Ashfield R, Wiltshire S, Turner RC. Association studies of variants in promoter and coding regions of β-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53). Diabet. Med.18(3), 206–212 (2001).
   PubMed Web of Science ®Google Scholar
• Florez JC, Burtt N, de Bakker PI et al. Haplotype structure and genotype–phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. Diabetes53(5), 1360–1368 (2004).
   PubMed Web of Science ®Google Scholar
• Nielsen EM, Hansen L, Carstensen B et al. The E23K variant of Kir6.2 associates with impaired post-OGTT serum insulin response and increased risk of Type 2 diabetes. Diabetes52(2), 573–577 (2003).
   PubMed Web of Science ®Google Scholar
• Schwanstecher C, Meyer U, Schwanstecher M. K(IR)6.2 polymorphism predisposes to Type 2 diabetes by inducing overactivity of pancreatic β-cell ATP-sensitive K+ channels. Diabetes51(3), 875–879 (2002).
   Google Scholar
• Inoue H, Ferrer J, Warren-Perry M et al. Sequence variants in the pancreatic islet β-cell inwardly rectifying K+ channel Kir6.2 (Bir) gene: identification and lack of role in Caucasian patients with NIDDM. Diabetes46(3), 502–507 (1997).
   Google Scholar
• Barroso I, Luan J, Middelberg RP et al. Candidate gene association study in Type 2 diabetes indicates a role for genes involved in β-cell function as well as insulin action. PLoS Biol.1(1), E20 (2003).
   PubMed Web of Science ®Google Scholar
• Sesti G, Laratta E, Cardellini M et al. The E23K variant of KCNJ11 encoding the pancreatic β-cell adenosine 5´-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with Type 2 diabetes. J. Clin. Endocrinol. Metab.91(6), 2334–2339 (2006).
   PubMed Web of Science ®Google Scholar
• Holstein A, Hahn M, Stumvoll M, Kovacs P. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with Type 2 diabetes. Horm. Metab. Res.41(5), 387–390 (2009).
   PubMedGoogle Scholar
• Hamming KS, Soliman D, Matemisz LC et al. Coexpression of the Type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K+ channel. Diabetes58(10), 2419–2424 (2009).
   PubMed Web of Science ®Google Scholar
• Grant RW, Moore AF, Florez JC. Genetic architecture of Type 2 diabetes: recent progress and clinical implications. Diabetes Care32(6), 1107–1114 (2009).
   PubMed Web of Science ®Google Scholar
• Jin T. The WNT signalling pathway and diabetes mellitus. Diabetologia51(10), 1771–1780 (2008).
   PubMedGoogle Scholar
• Grant SF, Thorleifsson G, Reynisdottir I et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of Type 2 diabetes. Nat. Genet.38(3), 320–323 (2006).
   PubMed Web of Science ®Google Scholar
• Tong Y, Lin Y, Zhang Y, Yang J, Liu H, Zhang B. Association between TCF7L2 gene polymorphisms and susceptibility to Type 2 diabetes mellitus: a large Human Genome Epidemiology (HuGE) review and meta-analysis. BMC Med. Genet.10, 15 (2009).
   PubMed Web of Science ®Google Scholar
• Pearson ER. Translating TCF7L2: from gene to function. Diabetologia52(7), 1227–1230 (2009).
   Google Scholar
• Lyssenko V, Lupi R, Marchetti P et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of Type 2 diabetes. J. Clin. Invest.117(8), 2155–2163 (2007).
   PubMed Web of Science ®Google Scholar
• Hattersley AT, Pearson ER. Minireview: pharmacogenetics and beyond: the interaction of therapeutic response, β-cell physiology, and genetics in diabetes. Endocrinology147(6), 2657–2663 (2006).
   PubMed Web of Science ®Google Scholar
• Pearson ER, Donnelly LA, Kimber C et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes56(8), 2178–2182 (2007).
   PubMed Web of Science ®Google Scholar
• Jellema A, Zeegers MP, Feskens EJ, Dagnelie PC, Mensink RP. Gly972Arg variant in the insulin receptor substrate-1 gene and association with Type 2 diabetes: a meta-analysis of 27 studies. Diabetologia46(7), 990–995 (2003).
   PubMed Web of Science ®Google Scholar
• Zeggini E, Parkinson J, Halford S et al. Association studies of insulin receptor substrate 1 gene (IRS1) variants in Type 2 diabetes samples enriched for family history and early age of onset. Diabetes53(12), 3319–3322 (2004).
   Google Scholar
• Florez JC, Sjogren M, Burtt N et al. Association testing in 9,000 people fails to confirm the association of the insulin receptor substrate-1 G972R polymorphism with Type 2 diabetes. Diabetes53(12), 3313–3318 (2004).
   Google Scholar
• Porzio O, Federici M, Hribal ML et al. The Gly972-->Arg amino acid polymorphism in IRS-1 impairs insulin secretion in pancreatic β cells. J. Clin. Invest.104(3), 357–364 (1999).
   PubMedGoogle Scholar
• Marchetti P, Lupi R, Federici M et al. Insulin secretory function is impaired in isolated human islets carrying the Gly(972)-->Arg IRS-1 polymorphism. Diabetes51(5), 1419–1424 (2002).
   PubMed Web of Science ®Google Scholar
• Sesti G, Marini MA, Cardellini M et al. The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with Type 2 diabetes. Diabetes Care27(6), 1394–1398 (2004).
   PubMed Web of Science ®Google Scholar
• Schulz R, Rassaf T, Massion PB, Kelm M, Balligand JL. Recent advances in the understanding of the role of nitric oxide in cardiovascular homeostasis. Pharmacol. Ther.108(3), 225–256 (2005).
   Google Scholar
• Massion PB, Pelat M, Belge C, Balligand JL. Regulation of the mammalian heart function by nitric oxide. Comp. Biochem. Physiol. A Mol. Integr. Physiol.142(2), 144–150 (2005).
   Google Scholar
• Lajoix AD, Reggio H, Chardes T et al. A neuronal isoform of nitric oxide synthase expressed in pancreatic β-cells controls insulin secretion. Diabetes50(6), 1311–1323 (2001).
   PubMed Web of Science ®Google Scholar
• Gunawardana SC, Rocheleau JV, Head WS, Piston DW. Mechanisms of time-dependent potentiation of insulin release: involvement of nitric oxide synthase. Diabetes55(4), 1029–1033 (2006).
   Google Scholar
• Becker ML, Aarnoudse AJ, Newton-Cheh C et al. Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylurea. Pharmacogenet. Genomics18(7), 591–597 (2008).
   Google Scholar
• Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet362(9392), 1275–1281 (2003).
   PubMed Web of Science ®Google Scholar